Clinical Trial

Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study

Study acronym: PCOSMG53
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated August 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
Purpose of the Study: This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS). MG53 is involved in cell membrane repair and may play a role in insulin resistance, which is common in PCOS. Study Procedures: Women between 18 and 45 years of age will be invited to participate. The study population will include both women diagnosed with PCOS and healthy controls. A single blood sample (approximately 5 mL) will be collected from each participant. MG53 levels will be measured using an ELISA laboratory assay. Significance of the Study: Analysis of MG53 levels in relation to hormonal and metabolic markers may help determine whether MG53 is associated with insulin resistance and other characteristics of PCOS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-23.
Trial Details
NCT Number NCT07094776
Lead Sponsor Havva Betül Bacak
Conditions Polycystic Ovary Syndrome (PCOS), Insulin Resistance Syndrome
Enrollment 128 participants
Start Date 2025-06-18
Primary Completion 2025-08-20 (estimated)
Study Completion 2025-08-20 (estimated)
Updated on ClinicalTrials.gov 2025-08-06